TGThomas Goddard

Thomas Goddard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Goddard has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation

    by Jessica A. P. Carlson-Jones, Thomas R. Goddard, Bhavya Papudeshi, Vijini Mallawaarachchi, Katrine L. Whiteson, Morgyn S. Warner, Judith M. Morton, Hubertus P. A. Jersmann, Robert A. Edwards

    SUMMARY: DNA sequencing has revolutionized microbial surveillance in cystic fibrosis (CF), transforming pathogen identification from culture-dependent to total microbial community identification using molecular-based approaches. Techniques such as 16S rRNA gene sequencing have uncovered the complexity of the CF airway microbiome, while shotgun metagenomics, metatranscriptomics, and viromics now provide strain-level, functional, and viral insights beyond bacterial identification. Despite these advances, key technical and logistical challenges remain, including the processing of high-viscosity sputum samples, overwhelming host DNA contamination, managing large data sets, and the integration of complex bioinformatic outputs into clinical workflows. Emerging innovations such as host DNA depletion protocols, targeted enrichment panels, and adaptive sampling on Oxford Nanopore platforms are helping to overcome these barriers, improving microbial recovery and sequencing efficiency. As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies are changing the lives of people with cystic fibrosis (pwCF), sequencing offers an unprecedented opportunity to track potential microbial adaptation in response. This review investigates current advances, limitations, and translational opportunities in DNA sequencing for CF airway microbiome surveillance, highlighting how these technologies can help reshape research and clinical microbiology in the post-modulator era.

  • Open Access

    Microbial Ecological Signatures Predict Pathogen Emergence and Multidrug Resistance in Cystic Fibrosis Airways up to a Year in Advance

    by Thomas R. Goddard, Jessica Ap. Carlson-Jones, Judith Morton, Chee Y. Ooi, Andrew Tai, Morgyn S. Warner, John Wong, Ieuan Es. Evans, Emily Hopkins, Jonathan R. Iredell, et al.

    Chronic infections in cystic fibrosis (CF) emerge from gradual ecological transitions in the airway microbiome, yet early predictive markers remain poorly defined. We developed a new autoencoder-based framework that outperforms read-based or metagenome-assembled genome-based analyses at capturing the continuum from health-associated commensals to pathogen-dominated, antibiotic-tolerant communities. This improvement is achieved by integrating taxonomic and functional data from 127 sputum and bronchoalveolar lavage metagenomes from 64 people with CF into latent “Clusters of Phylogeny and Functions” (COPFs). Coupled with gradient-boosted random forests, COPFs predicted Pseudomonas aeruginosa colonisation, multidrug resistance, and impending infection up to a year before clinical detection. The multidrug-resistant P. aeruginosa signature showed the same resistance-mechanism evolution as found in laboratory experiments. The inclusion of eukaryotic markers revealed persistent Aspergillus fumigatus signatures even during culture-negative intervals. Applying our South Australian-trained model to over 1,000 global metagenomes from 22 independent CF datasets, we achieved 94% accuracy in predicting P. aeruginosa status across platforms and geographies, validating the model’s universal utility. Our results demonstrate that combining datasets with deep learning reveals conserved ecological and metabolic mechanisms in disease progression, transforming metagenomics into a predictive framework for managing chronic infections.


  • Open Access

    Drug treatment of cystic fibrosis

    by Matthew Bruorton, Thomas Goddard

    The life expectancy of patients with cystic fibrosis has improved so much, they are now experiencing chronic health conditions such as cardiovascular disease.


  • A randomized controlled trial of a structured exercise intervention after the completion of acute cancer treatment in adolescents and young adults

    by Morgan Atkinson, Andrew Murnane, Thomas Goddard, Cathy Pendergrast, Paul Rogers, Rebecca Manudhane, Michael Osborn

    Background: Cancer treatments are frequently associated with impaired physical fitness, quality of life (QOL), and fatigue, often persisting into survivorship. Studies in older adults with cancer have demonstrated benefits from exercise; however, this has not been rigorously investigated in adolescents and young adults (AYA). The aim of this study was to determine whether a structured 10‐week exercise intervention was associated with improved cardiorespiratory fitness (VO2peak), fatigue, and QOL in AYA who have recently completed cancer treatment.Method: Forty‐three AYA (median age 21 ± 6 years) were randomly assigned to an exercise group (n = 22) or a control group (n = 21). The exercise group received a structured 10‐week exercise program comprising progressive aerobic and resistance exercise; the control arm received routine care. VO2peak was measured at baseline, 10 weeks, and six months. Fatigue and QOL were assessed by the FACIT fatigue scale and the PEDS QL, respectively.Results: Mean VO2peak at baseline was 26.5 ± 7.2 mL.kg−1.min−1, which is substantially lower than population norms. The exercise group demonstrated significant improvement in VO2peak at 10 weeks compared with controls (33.8 ± 8.1 vs 29.6 ± 7.6 mL.kg−1.min−1, P = 0.0002), but by six months, the difference was no longer significant (32.9 ± 7.0 vs 30.9 ± 11.0 mL.kg−1.min−1, P = 0.21). There were no significant differences in fatigue or total QOL scores between groups.Conclusion: Cancer treatment is associated with reduced VO2peak in AYA. Improvement in VO2peak was accelerated by a 10‐week exercise program; however, no significant benefit was observed in QOL or fatigue. The plateau in VO2peak at six months suggests that a maintenance exercise program may be beneficial.


  • Successful survival of an extreme premature infant with cystic fibrosis

    by Thomas Goddard, Chad Andersen, Andrew Tai

    Extreme premature infants with cystic fibrosis typically do not survive the neonatal phase. This case report describes the youngest survivor of a premature infant with cystic fibrosis and highlights the importance of advanced neonatal care with cystic fibrosis therapy.


  • Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples

    by Gianny P. Scoleri, Jocelyn M. Choo, Lex E. X. Leong, Thomas R. Goddard, Lisa Shephard, Lucy D. Burr, Ivan Bastian, Rachel M. Thomson, Geraint B. Rogers

    Culture-based detection of nontuberculous Mycobacteria (NTM) in respiratory samples is time consuming and can be subject to overgrowth by nonmycobacterial bacteria. We describe a single-reaction TaqMan quantitative PCR assay for the direct detection of NTM species in clinical samples that is specific, sensitive, and robust.


  • Case 2: A Late Preterm Newborn with Cyanosis

    by Marcus Brecht, Thomas Goddard, Dylan Mordaunt, Andrew Kelly, Christopher Barnett